Cargando…

Impaired response to first SARS‐CoV‐2 dose vaccination in myeloproliferative neoplasm patients receiving ruxolitinib

Detalles Bibliográficos
Autores principales:	Guglielmelli, Paola, Mazzoni, Alessio, Maggi, Laura, Kiros, Seble Tekle, Zammarchi, Lorenzo, Pilerci, Sofia, Rocca, Arianna, Spinicci, Michele, Borella, Miriam, Bartoloni, Alessandro, Rossolini, Gian Maria, Annunziato, Francesco, Vannucchi, Alessandro M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons, Inc. 2021
Materias:	Correspondences
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8420430/ https://www.ncbi.nlm.nih.gov/pubmed/34331712 http://dx.doi.org/10.1002/ajh.26305

Ejemplares similares

Humoral and cellular responses after third dose of SARS-CoV-2 vaccine in myeloproliferative neoplasms patients on ruxolitinib therapy
por: Atanasio, A., et al.
Publicado: (2023)

SARS-CoV-2 infection and vaccination trigger long-lived B and CD4(+) T lymphocytes with implications for booster strategies
por: Mazzoni, Alessio, et al.
Publicado: (2022)

Clinical and Immunological Features of SARS-CoV-2 Breakthrough Infections in Vaccinated Individuals Requiring Hospitalization
por: Lamacchia, Giulia, et al.
Publicado: (2022)

Recent advances in diagnosis and treatment of chronic myeloproliferative neoplasms
por: Guglielmelli, Paola, et al.
Publicado: (2010)

Heterogeneous magnitude of immunological memory to SARS‐CoV‐2 in recovered individuals
por: Mazzoni, Alessio, et al.
Publicado: (2021)

Chronic Myeloproliferative Neoplasms: a Collaborative Approach
por: Pieri, Lisa, et al.
Publicado: (2010)

Serum NMR Profiling Reveals Differential Alterations in the Lipoproteome Induced by Pfizer-BioNTech Vaccine in COVID-19 Recovered Subjects and Naïve Subjects
por: Ghini, Veronica, et al.
Publicado: (2022)

Epigenetic therapy in myeloproliferative neoplasms: evidence and perspectives
por: Vannucchi, Alessandro M, et al.
Publicado: (2009)

Acute Myocardial Infarction and Chronic Myeloproliferative Neoplasms: Friend and Enemy, Depending on Circumstances
por: Vannucchi, Alessandro Maria, et al.
Publicado: (2023)

Integration of Molecular Information in Risk Assessment of Patients with Myeloproliferative Neoplasms
por: Loscocco, Giuseppe G., et al.
Publicado: (2021)

Fourth Dose of mRNA COVID-19 Vaccine Transiently Reactivates Spike-Specific Immunological Memory in People Living with HIV (PLWH)
por: Lamacchia, Giulia, et al.
Publicado: (2022)

Impact of Mutational Profile on the Management of Myeloproliferative Neoplasms: A Short Review of the Emerging Data
por: Loscocco, Giuseppe G, et al.
Publicado: (2020)

Long-term SARS-CoV-2 Asymptomatic Carriage in an Immunocompromised Host: Clinical, Immunological, and Virological Implications
por: Spinicci, Michele, et al.
Publicado: (2022)

Low risk of serological cross-reactivity between dengue and COVID-19
por: Spinicci, Michele, et al.
Publicado: (2020)

Compassionate use of JAK1/2 inhibitor ruxolitinib for severe COVID-19: a prospective observational study
por: Vannucchi, Alessandro M., et al.
Publicado: (2020)

Concomitant JAK2 mutated myeloproliferative neoplasms and hereditary hemochromatosis
por: Loscocco, Giuseppe G., et al.
Publicado: (2022)

High mortality rate in COVID-19 patients with myeloproliferative neoplasms after abrupt withdrawal of ruxolitinib
por: Barbui, Tiziano, et al.
Publicado: (2021)

Pharmacobiological Approach for the Clinical Development of Ruxolitinib in Myeloproliferative Neoplasms
por: Eliaçık, Eylem, et al.
Publicado: (2015)

Critical appraisal of the role of ruxolitinib in myeloproliferative neoplasm-associated myelofibrosis
por: Barosi, Giovanni, et al.
Publicado: (2015)

The 2016 WHO classification and diagnostic criteria for myeloproliferative neoplasms: document summary and in-depth discussion
por: Barbui, Tiziano, et al.
Publicado: (2018)

mTOR Inhibitors Alone and in Combination with JAK2 Inhibitors Effectively Inhibit Cells of Myeloproliferative Neoplasms
por: Bogani, Costanza, et al.
Publicado: (2013)

Zika Virus: a Review from the Virus Basics to Proposed Management Strategies
por: Zammarchi, Lorenzo, et al.
Publicado: (2016)

The Importance of Updating and Continuous Education on Imported Emerging Diseases
por: Zammarchi, Lorenzo, et al.
Publicado: (2017)

Biology and Clinical Management of Myeloproliferative Neoplasms and Development of the JAK Inhibitor Ruxolitinib
por: Mascarenhas, J, et al.
Publicado: (2012)

SARS-CoV-2 Spike-Specific CD4+ T Cell Response Is Conserved Against Variants of Concern, Including Omicron
por: Mazzoni, Alessio, et al.
Publicado: (2022)

Soccer in the time of COVID-19: 1 year report from an Italian top league club, March 2020–February 2021
por: Spinicci, Michele, et al.
Publicado: (2021)

International Consensus Classification of myeloid and lymphoid neoplasms: myeloproliferative neoplasms
por: Gianelli, Umberto, et al.
Publicado: (2022)

Cerebral venous thrombosis and myeloproliferative neoplasms: A three‐center study of 74 consecutive cases
por: Gangat, Naseema, et al.
Publicado: (2021)

Combination regimen of nirmatrelvir/ritonavir and molnupiravir for the treatment of persistent SARS-CoV-2 infection: A case report and a scoping review of the literature
por: Marangoni, Davide, et al.
Publicado: (2023)

Scalp eschar and neck lymph adenopathy after a tick bite (SENLAT) in Tuscany, Italy (2015–2022)
por: Barbiero, Anna, et al.
Publicado: (2023)

The Implications of Liver Biopsy Results in Patients with Myeloproliferative Neoplasms Being Treated with Ruxolitinib
por: Tremblay, Douglas, et al.
Publicado: (2019)

Letter to the Editor Regarding Management of Adult Patients with COVID-19 Outside Intensive Care Units: Guidelines from the Italian Society of Anti-Infective Therapy (SITA) and the Italian Society of Pulmonology (SIP)
por: Manciulli, Tommaso, et al.
Publicado: (2021)

Tuberculosis in the European Region
por: Mencarini, Jessica, et al.
Publicado: (2023)

Ruxolitinib: Long-Term Management of Patients with Myelofibrosis and Future Directions in the Treatment of Myeloproliferative Neoplasms
por: Yacoub, A., et al.
Publicado: (2014)

High Incidence of Herpes Zoster in Patients Using Ruxolitinib for Myeloproliferative Neoplasms: Need for Prophylaxis
por: te Linde, Elsemieke, et al.
Publicado: (2022)

Blast phase myeloproliferative neoplasm with prior exposure to ruxolitinib: comparative analysis of mutations and survival
por: Abdelmagid, Maymona G., et al.
Publicado: (2023)

Patterns of Ruxolitinib Therapy Failure and Its Management in Myelofibrosis: Perspectives of the Canadian Myeloproliferative Neoplasm Group
por: Gupta, Vikas, et al.
Publicado: (2020)

Arbo-Score: A Rapid Score for Early Identification of Patients with Imported Arbovirosis Caused by Dengue, Chikungunya and Zika Virus
por: Vellere, Iacopo, et al.
Publicado: (2020)

Mutation landscape in patients with myelofibrosis receiving ruxolitinib or hydroxyurea
por: Pacilli, Annalisa, et al.
Publicado: (2018)

Strongyloidiasis in Children Outside the Tropics: Do We Need to Increase Awareness?
por: Venturini, Elisabetta, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_a3dmf76a8h50u03rb29u8297ff